Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]

  • In development
  • GID-TA11570
  • Expected publication date: 

NICE is considering whether new evidence has emerged that would affect the recommendation of TA909.

Documents